When Group Health patients received support from a nurse navigator, or advocate, soon after a cancer diagnosis, they had better experiences and fewer problems with their care-particularly in health information, care coordination, and psychological and social care-according to a randomized controlled trial in the Journal of Clinical Oncology.
Data for tiotropium show improved lung function, sustained bronchodilation in patients with moderate asthma severity.
Implementation of the new rule will likely reduce plans’ costs.
How organizations can overcome challenges of reporting, capturing patient data.
National insurers are betting on new tech tools to click with members
A fraction of consumers who could be buying plans actually did
Understand the culturally-embedded tendency to be reluctant to seek medical treatment
About 17 million consumers will be eligible for subsidies in exchanges
Blue Shield of California ACOs report 3% trend
Critical care patients have higher HAI rates
Sudden change requires plans to weigh financial impact
Confused members might opt for the worst choice under ACA
Be mindful of data breaches with cloud-based systems
Study investigates performance gaps between dual-eligible and non dual-eligible patients.
FDA has eased restrictions on patient access to the controversial diabetes drug rosiglitazone (Avandia, GlaxoSmithKline). The agency made its determination after an FDA Advisory Committee reviewed the drug in June 2013 and voted to lift its restrictions, and new information was released indicating that the drug carries no heightened cardiovascular risk.
Payment cuts to Medicare Advantage prompt plans to narrow their networks.
Network selection is one tool plans are using to overcome cost pressures
FDA is warning healthcare professionals of the rare but serious risk of heart attack and death with use of cardiac nuclear stress test agents regadenoson (Lexiscan) and adenosine (Adenoscan).
FDA has requested label and packaging changes for certain over-the-counter (OTC) topical antiseptic products to decrease the risk of infections from these products, which in rare cases have resulted in deaths.
UnitedHealthcare and other plans are dropping network providers
Plans are looking to lock in only high value providers
The following states are allowing local insurers the option to continue non-grandfathered plans through 2014.
FDA has approved luliconazole (Luzu Cream, 1%, Valeant Pharmaceuticals) for the 1-week, once-daily treatment of interdigital tinea pedis, tinea cruris, and tinea corporis, caused by the organisms Trichophyton rubrum and Epidermophyton floccosum, in patients aged 18 years and older.
Excessive analgesics use can contribute to the chronic headache associated with concussion in some adolescent patients and discontinuing these drugs can improve symptoms, according to researchers at the 42nd Annual Meeting of the Child Neurology Society, in Austin, Texas.
Women using oral contraceptive for 3 years or more may be at risk for developing glaucoma and should be screened for the eye disease if they have additional risk factors, according to researchers at the American Academy of Ophthalmology annual meeting in New Orleans.
Proposal to allow individuals with non-grandfathered plans to keep their policies through 2014 has left insurers in highly variable situations.
Today, Blue Cross and Blue Shield of North Carolina filed the paperwork to extend non-grandfathered plans through 2014.
Operational and economic consequences of extending non-grandfathered plans must be considered.
Lurasidone HCl (Latuda) reduces depressive symptoms in adult patients with bipolar depression as monotherapy and adjunctive therapy to lithium or valproate. This flexibility is important given the multiple unmet needs of patients with bipolar depression, according to 2 phase 3 studies published recently in The American Journal of Psychiatry.
FDA has approved ibrutinib (Imbruvica, Pharmacyclics and Janssen) to treat patients with mantle cell lymphoma (MCL), a rare and aggressive type of blood cancer. It is the second drug with breakthrough therapy designation to receive FDA approval.